STAT C 007, a German infusion that had lifted hope of patients, is heading for new study. After years with long Covid — debilitated by fatigue, headaches, and neurological issues — her symptoms dramatically receded. While not fully back to her pre-Covid-19 baseline, she was able to resume university classes and other daily activities.
“In the last few months, I have literally regained life,” Bhalla said in an interview last November.
Bhalla posted on social media about her experience, garnering attention from other people with long Covid who hoped they could benefit from the same drug: an infusion called BC 007 (or rovunaptabin). Berlin Cures, the company that developed this drug, had repurposed it from heart disease research, hypothesizing that it could alleviate symptoms by reducing autoantibodies — immune system components that mistakenly attack the body as if it is an outside invader.